Juan Velazquez, MD
Family Medicine · San Antonio, TXNPI 1396906731
Payments from drug & device makers
Across 95 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$452
- Sunovion Pharmaceuticals Inc.$308
- Sanofi-aventis U.S. LLC$293
- Lilly USA, LLC$220
- GSK$88
- Abiomed$80
- plus $284 from 10 others
What the payments were for
- Food & beverage$1,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $452 |
| Sunovion Pharmaceuticals Inc. | 15 | $308 |
| Sanofi-aventis U.S. LLC | 18 | $293 |
| Lilly USA, LLC | 20 | $220 |
| GSK | 5 | $88 |
| Abiomed | 2 | $80 |
| Novo Nordisk | 5 | $72 |
| AbbVie | 3 | $67 |
| Abbott | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| Pfizer | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Amgen | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$125
How this compares
$1,725 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 148 | $191,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $88,106 |
| OzempicSemaglutide | 65 | $68,617 |
| EliquisApixaban | 46 | $50,217 |
| JanuviaSitagliptin Phosphate | 31 | $50,105 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $47,006 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $43,233 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $42,261 |
| FarxigaDapagliflozin Propanediol | 23 | $36,980 |
| TrulicityDulaglutide | 21 | $36,182 |
| RybelsusSemaglutide | 31 | $34,978 |
| TradjentaLinagliptin | 20 | $29,505 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $24,562 |
| Spiriva HandihalerTiotropium Bromide | 21 | $24,470 |
| XareltoRivaroxaban | 17 | $20,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $220 | $227,266169 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $88 | $126,775214 claims |
| Novo NordiskOzempic, Rybelsus | $72 | $103,59596 claims |
| AstraZenecaFarxiga, Symbicort | $452 | $51,74384 claims |
| PfizerEliquis | $22 | $50,21746 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $293 | $42,26148 claims |
| Boehringer IngelheimTradjenta | $22 | $29,50520 claims |
| AbbVieLinzess | $67 | $13,74017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.